Do Tofacitinib Generics Exhibit Conventional Synthetic Disease-Modifying Anti-rheumatic Drug and Non-steroidal Anti-inflammatory Drug-Sparing Ability in the Management of Axial Spondyloarthritis?

Introduction: Tofacitinib has emerged as a therapeutic option for axial spondyloarthritis (axSpA) following successful clinical trials. The evidence on the efficacy of tofacitinib generics in the management of axSpA is limited. In India, the usage of conventional synthetic disease-modifying anti-rhe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganapati, Arvind, Arya, Suvrat, Gupta, Nikhil, Patil, Abhishek, Chebbi, Pramod, Doley, Daisy, Jeevanagi, Sachin R, Sahu, Rahul, Mandal, Santosh K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620471/
https://www.ncbi.nlm.nih.gov/pubmed/37927736
http://dx.doi.org/10.7759/cureus.46391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620471/
https://www.ncbi.nlm.nih.gov/pubmed/37927736
http://dx.doi.org/10.7759/cureus.46391

Ejemplares similares